DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: CHANTIX

Summary for Tradename: CHANTIX

Patents:3
Applicants:1
NDAs:1
Suppliers: see list7
drug
patent expirations by year for
 CHANTIX

Pharmacology for Tradename: CHANTIX

Clinical Trials for: CHANTIX

Varenicline as a Treatment for Methamphetamine Dependence
Status: Completed Condition: Methamphetamine Dependence; Methamphetamine Abuse; Substance Abuse

Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder
Status: Completed Condition: Smoking Cessation; Bipolar Disorder

Varenicline for Smoking Cessation in Heavy Drinking Smokers
Status: Completed Condition: Nicotine Dependence; Smoking; Heavy Drinking

Study of Mood Effects of Varenicline (Chantix) in Depressed Outpatient Smokers
Status: Completed Condition: Depressive Disorder; Smoking

Assessing the Impact of Varenicline on Brain-Behavior Vulnerability
Status: Active, not recruiting Condition: Varenicline and the Blunting of Cocaine Cues

Varenicline In-Patient Study
Status: Recruiting Condition: Smoking Cessation

A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.
Status: Completed Condition: Smoking Cessation

Tailoring Varenicline to Individual Needs (TVIN Study)
Status: Completed Condition: Tobacco Dependence; Smoking Cessation

Varenicline-Methamphetamine Interaction Study (2008)
Status: Withdrawn Condition: Methamphetamine Dependence; Substance Abuse; Methamphetamine Abuse

Varenicline Treatment for Active Alcoholic Smokers
Status: Completed Condition: Smoking; Tobacco Dependence; Alcohol Dependence

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928May 10, 2006RXNo<disabled><disabled>
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928May 10, 2006RXNo6,410,550<disabled>YY<disabled>
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928May 10, 2006RXNo6,890,927<disabled>YY<disabled>
Pfizer Inc
CHANTIX
varenicline tartrate
TABLET;ORAL021928May 10, 2006RXNo7,265,119<disabled>YY<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CHANTIX

Drugname Dosage Strength RLD Submissiondate
varenicline tartrateTablets0.5 mg and 1 mgChantix5/10/2010

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc